Emergent CEO sold more than $10 million in stock before scrapping J&J COVID-19 vaccine doses: report

Emergent BioSolutions has faced a number of back-to-back PR crises since production issues at its Baltimore facility placed the company under intense scrutiny. The CDMO's stock price has tumbled as a result, but it appears CEO Robert Kramer cashed out some of his shares just in time.

Citing SEC filings, Kramer sold more than $10 million worth of Emergent stock in January and early February, right before the company’s shares began to tumble following its quarterly earnings reported on February 19, The Washington Post reports.